Article Text

PDF

Cardioselective β blockers do not cause adverse respiratory effects in mild to moderate reactive airway disease
  1. E Gamble
  1. lizgamble{at}cwcom.net

Statistics from Altmetric.com

This study examined data from 19 studies of single dose treatment and 10 studies of continued treatment with cardioselective β blockers (atenolol, metoprolol, bisoprolol, practolol, celiprolol, acebutolol and xamoterol) in patients with reactive airway disease (asthma or COPD with reversible obstruction). After single dose administration there was a 7.46% decrease in FEV1 and a 4.63% increase in FEV1 response to β agonist compared with placebo with no increase in symptoms. In trials lasting 3 days to 4 weeks no significant changes were seen in FEV1, symptoms, or inhaler use, but β agonist response was increased by 8.74%. No significant treatment effect on FEV1 was found in patients with COPD.

Cardioselective β blockers do not cause clinically significant adverse respiratory effects in patients with mild to moderate reactive airway disease, including COPD. In view of the demonstrated benefits in cardiovascular disease, such treatment should not be withheld in this group of patients.

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.